All In Biotech

Drug Trial Radar · NCT07515079

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema

A Multicenter, Randomized, Double-Blind Phase III Clinical Study Comparing the Efficacy and Safety of BAT5906 Versus Ranibizumab (Lucentis®) in Patients With Diabetic Macular Edema (DME)

Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 406 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

406

Planned (sponsor's estimate)

Start

Oct 9, 2024

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Apr 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, parallel-group, active-controlled non-inferiority trial. A total of 406 subjects with diabetic macular edema (DME) were planned for enrollment. After screening, eligible subjects were randomized in a 1:1 ratio to the treatment group or the control group. The treatment group received BAT5906 injection, while the control group received Lucentis®. During the trial, ophthalmic examinations and safety assessments were conducted according to the protocol for efficacy and safety evaluation. Blood samples were collected for immunogenicity assessment. The primary endpoint was the mean change in best-corrected visual acuity (BCVA) in the study eye from baseline to week 52 (measured using the ETDRS chart).

Conditions

  • Diabetic Macular Edema (DME)

Interventions

  • BAT5906 injectionDrug

    4.0 mg/eye/time, 50 μl, intravitreal injection

  • LucentisDrug

    0.5 mg/eye/time, 50 μl, intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in the BCVA valueTime frame: Week 52

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Aier Yingzhi Eye Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Gansu Provincial People's Hospital

    Lanzhou, Gansu, China · Active not recruiting

  • The Second Hospital of Lanzhou University

    Lanzhou, Gansu, China · Recruiting

  • Guangzhou Aier Eye Hospital

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Shantou University-The Chinese University of Hong Kong Joint Shantou International Eye Center

    Shantou, Guangdong, China · Recruiting

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China · Recruiting

  • Guangxi Zhuang Autonomous Region People's Hospital

    Nanning, Guangxi, China · Recruiting

  • Zunyi Medical University Affiliated Hospital

    Zunyi, Guizhou, China · Recruiting

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China · Recruiting

  • Shijiazhuang Municipal People's Hospital

    Shijiazhuang, Hebei, China · Recruiting

  • Hebei Eye Hospital

    Xingtai, Hebei, China · Recruiting

  • Luoyang Third People's Hospital

    Luoyang, Henan, China · Recruiting

  • Henan Eye Center (Henan Provincial Eye Hospital)

    Zhengzhou, Henan, China · Recruiting

  • Zhengzhou Second People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Wuhan Central Hospital

    Wuhan, Hubei, China · Recruiting

  • Wuhan Puren Hospital

    Wuhan, Hubei, China · Recruiting

  • Wuhan University People's Hospital (Hubei Provincial People's Hospital)

    Wuhan, Hubei, China · Recruiting

  • Changsha Aier Eye Hospital

    Changsha, Hunan, China · Recruiting

  • Nanjing Medical University Eye Hospital

    Nanjing, Jiangsu, China · Terminated

  • Wuxi Municipal People's Hospital

    Wuxi, Jiangsu, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • The Second Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Panjin Liaoyang Gem Flower Hospital

    Panjin, Liaoning, China · Recruiting

  • Shenyang Fourth People's Hospital

    Shenyang, Liaoning, China · Recruiting

  • Inner Mongolia Medical University Affiliated Hospital

    Neimeng, Neimenggu, China · Recruiting

  • Jinan Second People's Hospital

    Jinan, Shandong, China · Recruiting

  • Shandong University of Traditional Chinese Medicine Affiliated Eye Hospital

    Jinan, Shandong, China · Recruiting

  • Weifang Eye Hospital

    Weifang, Shandong, China · Recruiting

  • Weifang Medical University Affiliated Hospital

    Weifang, Shandong, China · Recruiting

  • Longhua Hospital Affiliated with Shanghai University of Traditional Chinese Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Eye Disease Prevention and Treatment Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai First People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Provincial Eye Hospital

    Taiyuan, Shanxi, China · Recruiting

  • Xi'an First Hospital

    Xi’an, Shanxi, China · Recruiting

  • Xi'an Fourth Hospital

    Xi’an, Shanxi, China · Recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.